163 related articles for article (PubMed ID: 36989455)
1. Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy.
Igho-Osagie E; Puenpatom A; Williams MG; Song Y; Yi D; Wang J; Berman R; Gu M; He C
J Manag Care Spec Pharm; 2023 May; 29(5):509-518. PubMed ID: 36989455
[No Abstract] [Full Text] [Related]
2. Prevalence of Potential Drug-drug Interactions With Ritonavir-containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey.
Igho-Osagie E; Brzozowski K; Jin H; Brown J; Williams MG; Puenpatom A
Clin Ther; 2023 May; 45(5):390-399.e4. PubMed ID: 37032225
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
[No Abstract] [Full Text] [Related]
4. Real-world prevalence and consequences of potential drug-drug interactions in the first-wave COVID-19 treatments.
Martínez-López-de-Castro N; Samartín-Ucha M; Paradela-Carreiro A; Pérez-Landeiro A; Inaraja-Bobo MT; Álvarez-Payero M; Castro-Núñez I; García-Beloso N; Robles-Torres D; López-López A; González-Costas S; Leboreiro-Enríquez B; Otero-Millán L; Yaiza Romero-Ventosa E; Casanova-Martínez C; Lorenzo-Lorenzo K; Regueira-Arcay AM; Vázquez-López C; Martínez-Reglero C; Piñeiro-Corrales G
J Clin Pharm Ther; 2021 Jun; 46(3):724-730. PubMed ID: 33368439
[TBL] [Abstract][Full Text] [Related]
5. Individuals at risk for severe COVID-19 in whom ritonavir-containing therapies are contraindicated or may lead to interactions with concomitant medications: a retrospective analysis of German health insurance claims data.
Lübbert C; Dykukha I; Pelz JP; Yearley H; Junker W; Gruber N; Escher S; Biereth K; Melnik S; Puschmann J
Drugs Context; 2023; 12():. PubMed ID: 37415918
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer.
West H; Hu X; Zhang S; Song Y; Chirovsky D; Gao C; Lerner A; Jiang A; Signorovitch J; Samkari A
J Manag Care Spec Pharm; 2023 Jul; 29(7):749-757. PubMed ID: 37404067
[No Abstract] [Full Text] [Related]
7. Potential drug-drug interactions in internal medicine wards in hospital setting in Pakistan.
Ismail M; Iqbal Z; Khattak MB; Khan MI; Arsalan H; Javaid A; Gul Q; Khan F
Int J Clin Pharm; 2013 Jun; 35(3):455-62. PubMed ID: 23483444
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
[No Abstract] [Full Text] [Related]
9. Prevalence and nature of potential drug-drug interactions among hospitalized HIV patients presenting with suspected meningitis in Uganda.
Eneh PC; Hullsiek KH; Kiiza D; Rhein J; Meya DB; Boulware DR; Nicol MR
BMC Infect Dis; 2020 Aug; 20(1):572. PubMed ID: 32758158
[TBL] [Abstract][Full Text] [Related]
10. Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain.
Cantudo-Cuenca MD; Gutiérrez-Pizarraya A; Pinilla-Fernández A; Contreras-Macías E; Fernández-Fuertes M; Lao-Domínguez FA; Rincón P; Pineda JA; Macías J; Morillo-Verdugo R
Sci Rep; 2021 Jun; 11(1):12414. PubMed ID: 34127740
[TBL] [Abstract][Full Text] [Related]
11. Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databases.
Mesa-Frias M; Rossi C; Emond B; Bookhart B; Anderson D; Drummond S; Wang J; Lefebvre P; Lamerato LE; Lafeuille MH
J Manag Care Spec Pharm; 2022 Jul; 28(7):753-765. PubMed ID: 35503888
[No Abstract] [Full Text] [Related]
12. Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older.
Ranzani A; Oreni L; Agrò M; van den Bogaart L; Milazzo L; Giacomelli A; Cattaneo D; Gervasoni C; Ridolfo AL
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):193-201. PubMed ID: 29767640
[TBL] [Abstract][Full Text] [Related]
13. Are patients with a nasally placed feeding tube at risk of potential drug-drug interactions? A multicentre cross-sectional study.
Gimenes FRE; Baysari M; Walter S; Moreira LA; Carvalho REFL; Miasso AI; Faleiros F; Westbrook J
PLoS One; 2019; 14(7):e0220248. PubMed ID: 31365563
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. Potential drug-drug interactions in infant, child, and adolescent patients in children's hospitals.
Feinstein J; Dai D; Zhong W; Freedman J; Feudtner C
Pediatrics; 2015 Jan; 135(1):e99-108. PubMed ID: 25511114
[TBL] [Abstract][Full Text] [Related]
16. Analysis of potential drug-drug interactions in medical intensive care unit patients.
Uijtendaal EV; van Harssel LL; Hugenholtz GW; Kuck EM; Zwart-van Rijkom JE; Cremer OL; Egberts TC
Pharmacotherapy; 2014 Mar; 34(3):213-9. PubMed ID: 24390929
[TBL] [Abstract][Full Text] [Related]
17. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
J Urol; 2023 Jul; 210(1):224-226. PubMed ID: 37119051
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and nature of potential drug-drug interactions among kidney transplant patients in a German intensive care unit.
Amkreutz J; Koch A; Buendgens L; Muehlfeld A; Trautwein C; Eisert A
Int J Clin Pharm; 2017 Oct; 39(5):1128-1139. PubMed ID: 28823018
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
Xing S; Batt K; Kuharic M; Bullano M; Caicedo J; Chakladar S; Markan R; Farahbakhshian S
J Manag Care Spec Pharm; 2023 Jun; 29(6):626-634. PubMed ID: 37276033
[No Abstract] [Full Text] [Related]
20. Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary team.
Molas E; Luque S; Retamero A; Echeverría-Esnal D; Guelar A; Montero M; Guerri R; Sorli L; Lerma E; Villar J; Knobel H
HIV Clin Trials; 2018 Feb; 19(1):1-7. PubMed ID: 29179644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
